Nuwellis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 14, 2022, details a material definitive agreement entered into by Nuwellis, Inc. (Nuwellis) with Ladenburg Thalmann & Co. Inc. The report covers a registered public offering of equity securities that closed on October 18, 2022.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $9.8 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Offering Price: $0.25 per Unit.
- Securities Issued:
- 20,994,044 shares of Common Stock (including 5,758,848 from the full exercise of the overallotment option).
- 23,157,124 shares of Series I Convertible Preferred Stock.
- Warrants to purchase 66,226,752 shares of Common Stock (including 8,638,272 from the overallotment option).
- Post-Offering Capitalization (as of Oct 18, 2022):
- 31,531,650 shares of Common Stock outstanding.
- 127 shares of Series F Preferred Stock (convertible into 508,000 shares of Common Stock).
- 23,157,124 shares of Series I Preferred Stock (convertible into 23,157,124 shares of Common Stock).
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. It is a transaction report regarding capital raising.
Material Changes and Dilutive Events
- Series F Anti-Dilution Adjustment: Due to the offering price of $0.25 being lower than the previous conversion price, the conversion price of the outstanding Series F Convertible Preferred Stock was reduced to $0.25 pursuant to full-ratchet anti-dilution protection.
- Warrant Terms: Warrants have an exercise price of $0.25 and include a one-time reset provision to 90% of the five-day volume-weighted average price 90 days after issuance. They also contain a "cashless" exercise mechanism and beneficial ownership limitations (4.99% or 9.99%).
- Lock-Up Period: The Company and its executive officers/directors are restricted from selling securities for 90 days following the closing, or 30 days after stockholder approval of a reverse stock split (whichever is later).
Outlook, Risks, and Contingencies
- Reverse Stock Split Contingency: Warrants are not exercisable until a reverse stock split is effected and approved by stockholders to permit full exercise under Nasdaq rules.
- Series I Preferred Stock Rights: Holders have limited voting rights but possess veto power over changes to their rights, amendments to charter documents affecting them, or increases in authorized Series I shares. The Company may force conversion if the Common Stock price exceeds 300% of the conversion price for 20 of 30 consecutive trading days.
- Indemnification: The Company has agreed to indemnify the Underwriter against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the exact number of shares outstanding and the impact of the Series F anti-dilution adjustment on existing preferred shareholders.
- Confirm the timeline and likelihood of the required reverse stock split to enable warrant exercisability.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification clauses.
- Assess the dilution impact of the 66+ million warrants and the convertible Series I Preferred Stock on future earnings per share.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.